Dr. Todd Maderis, ND 

Exploring immune dysregulation, viral reactivation, mitochondrial impairment, and treatment implications in post-EBV fatigue syndromes.

Abstract

This article examines the role of Epstein–Barr virus (EBV) reactivation and immune exhaustion in the pathogenesis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). It reviews cytokine signatures, natural killer cell dysfunction, mitochondrial impairment, and current antiviral treatment considerations within a systems-based clinical framework.

Introduction

Epstein–Barr virus (EBV) is often dismissed as a self-limited infection. It is the most recognized cause of infectious mononucleosis, and approximately 95% of adults in the United States show evidence of prior exposure. For most individuals, the infection resolves, but for a considerable subset, it does not.

Prospective data demonstrate that up to 30% of patients develop persistent symptoms meeting criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) following infectious mononucleosis.¹ These patients often develop post-exertional malaise, unrefreshing sleep, cognitive dysfunction, autonomic instability, and immune dysregulation that can persist for years.

EBV Biology

EBV belongs to the herpesvirus family, alongside HHV-6, cytomegalovirus, herpes simplex virus, and varicella-zoster virus. Like all herpesviruses, EBV establishes lifelong latency.

During acute infection, EBV replicates within the host cell nucleus. After the lytic phase, it enters latency, residing in B lymphocytes. In this dormant state, it evades immune clearance. When immune surveillance weakens, EBV can reactivate and re-enter the lytic cycle.

The ability to switch between latency and reactivation contributes to EBV’s role in chronic immune activation.

Severity of Acute Infection Predicts Chronicity

Prospective research shows that the severity of the initial infectious mononucleosis episode strongly predicts the risk of prolonged fatigue.² Individuals with more intense inflammatory responses, as evidenced by elevated pro-inflammatory cytokines, during acute infection are significantly more likely to develop persistent symptoms.

Immune System Dysregulation in Epstein-Barr Virus

Cytokine profiling studies show that elevations in IL-10, TNF-α, IFN-γ, and IL-1β during acute EBV infection correlate with prolonged symptom duration.³ 

Another study demonstrated that greater illness severity was associated with pro-inflammatory cytokines in patients with chronic fatigue syndrome.⁴ This shows that there is a strong immune component associated with the symptomology in chronic fatigue syndrome.

Immune Exhaustion in EBV

A research study looking at signatures of immune exhaustion following EBV infection, including impaired T-cell functionality and diminished antiviral signaling. When cytotoxic T cells become functionally exhausted, the host’s ability to suppress latent viral reservoirs declines.

Natural killer (NK) cell dysfunction increases the problem. Reduced NK cell cytotoxic activity has been demonstrated in ME/CFS populations.⁵ Since NK cells play a critical role in controlling herpesviruses, this impairment may allow viral persistence or intermittent reactivation. 

EBV Reactivation – The Second Hit Model

Latent EBV is normally contained by the immune system. However, when immune regulation is disrupted, reactivation becomes more likely.

In individuals with Long COVID, 66.7% demonstrate evidence of EBV reactivation, compared with 10% in controls.⁶ This suggests that systemic immune stress has the potential to destabilize EBV latency.

Additional triggers of reactivation include:

• Chronic infections such as Lyme disease⁷
• Co-infections including Plasmodium falciparum, Helicobacter pylori, and Aspergillus flavus⁸
• Immunotoxic exposures such as mycotoxins⁹
• Elevated mercury burden and heavy metal–associated immune suppression¹⁰

Physiologic stress, sleep deprivation, and excessive exertion could also weaken antiviral surveillance.

The Role of EBV in ME/CFS

One of the most consistent findings in ME/CFS is impaired cellular energy production. Studies show defective oxidative phosphorylation in peripheral blood mononuclear cells from individuals with ME/CFS.¹¹ Prospective data in post-infectious fatigue syndromes further confirm metabolic abnormalities following EBV infection.¹

Mechanistically, EBV induces a feedback loop by reducing autophagy and reactive oxygen species (ROS), therefore further reducing autophagy.¹² Reduced autophagy disrupts mitochondrial quality control. Altered ROS dynamics additionally impair mitochondrial efficiency. This creates a feedback loop in which dysfunctional mitochondria generate abnormal signaling, which impairs cellular repair pathways, further reducing mitochondrial capacity.

Clinically, this presents as post-exertional malaise due to a failure to restore ATP production after physiologic stress.

Laboratory Considerations

Given the high prevalence of exposure to EBV, laboratory interpretation is nuanced.

Serology

Antibody titers to the Epstein-Barr virus can be tested through national reference laboratories. These commonly include:

• Viral capsid antigen (VCA) IgM
• VCA IgG
• Early antigen (EA) IgG
• EBV nuclear antigen (EBNA) IgG

Elevated IgG titers are expected in most adults, as 90% of people are exposed to the Epstein-Barr virus by early adulthood and do not indicate an active infection. Anti-EBNA IgG develops 2-4 months after infection and is detectable throughout life. Early antigen (EA) IgG and anti-VCA IgM are produced during a reactivated infection, driven by lytic gene expression. Anti-VCA IgM positivity suggests acute or active infection and warrants treatment.

PCR Testing

Detection of EBV DNA by PCR provides additional evidence of Epstein-Barr virus activity. Quantitative whole-blood PCR is preferred for evaluating suspected reactivation, as EBV resides intracellularly and whole-blood testing captures both cellular and plasma compartments. PCR testing may be more reliable when a patient is immunocompromised or has poor antibody response. I frequently use PCR testing along with serology when evaluating for EBV.

Cellular Immune Testing

T-cell functional assays measure T-cell production of interferon-γ and interleukin-2 in response to Epstein-Barr virus. I have found this valuable in my practice, but it is an out-of-pocket expense.  

Treatment Considerations

Pharmaceutical Antivirals

Valacyclovir has also demonstrated benefit in a subset of people with ME/CFS. In a placebo-controlled trial with 36-month follow-up, high-dose valacyclovir was associated with greater improvements in functional capacity and lower EBV VCA IgM titers than placebo.

Valganciclovir has shown clinical benefit in patients with chronic fatigue syndrome associated with EBV and HHV-6. In a randomized, placebo-controlled trial, valganciclovir-treated patients showed greater improvements in mental fatigue, overall fatigue severity, and cognitive function than placebo-treated patients. Clinical improvement was accompanied by reductions in monocyte counts and a shift toward a Th1 cytokine profile, suggesting immunomodulatory and antiviral effects.¹³

Supportive Oligonucleotide Therapy 

Supportive oligonucleotide therapy (SOT), also known as Q-REstrain, is a treatment that silences viral gene sequences required for replication. Unlike conventional antivirals, which rely on active viral activity and may be limited in latent infection states, oligonucleotides bind viral mRNA and prevent the production of viral replication proteins.

By targeting EBV gene regions, SOT reduces viral activity even when standard antivirals are ineffective. In my clinical experience, this therapy has proven to be the most consistently effective intervention for Epstein–Barr virus, particularly in patients with persistent immune activation or inadequate response to traditional antiviral medications.¹⁵

A Systems Perspective

Epstein–Barr virus should not be viewed as a past infection in patients with ME/CFS, but as a potential contributor to ongoing symptoms in a subset of people. In these individuals, the trajectory from Epstein-Barr virus exposure to chronic fatigue can be influenced by the intensity of the initial inflammatory response, the development of immune exhaustion, impaired viral surveillance, and mitochondrial dysfunction. Viral persistence or intermittent reactivation may perpetuate low-grade immune activation, while impairment in energy production is the hallmark feature of post-exertional malaise.

A comprehensive approach integrating antiviral therapy, immune modulation, and mitochondrial function offers the most effective treatment for patients with post-EBV ME/CFS.

---

Dr. Todd Maderis, ND is a licensed naturopathic physician and specialist in complex chronic illness with more than a decade of clinical experience focused on root-cause diagnosis and integrative care. He founded and serves as Medical Director of Marin Natural Medicine Clinic, where he treats challenging conditions including Lyme disease and tick-borne infections, chronic viral infections such as EBV and Long COVID, mold-related illness, mast cell activation syndrome (MCAS), and associated autoimmune and inflammatory disorders. Dr. Maderis emphasizes individualized assessment and sequential therapeutic strategies that integrate advanced testing, antimicrobial protocols, immune modulation, and systems-based support to restore resilience and quality of life. He is a board member of the International Society for Environmentally Acquired Illness (ISEAI) and a member of the International Lyme and Associated Diseases Society (ILADS) and the American Academy of Environmental Medicine (AAEM), reflecting his commitment to evidence-informed, multidisciplinary approaches to complex chronic disease care

---

References

1. Ruiz-Pablos M, Paiva B, Montero-Mateo R, Garcia N, Zabaleta A. Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome. Front Immunol. 2021;12:656797. doi:10.3389/fimmu.2021.656797.
2. Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575. doi:10.1136/bmj.38933.585764.AE.
3. Loebel M, Strohschein K, Giannini C, et al. Deficient EBV-specific B- and T-cell response in patients with chronic fatigue syndrome. PLoS One. 2014;9(1):e85387. doi:10.1371/journal.pone.0085387.
4. Montoya JG, Holmes TH, Anderson JN, et al. Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proc Natl Acad Sci U S A. 2017;114(34):E7150-E7158. doi:10.1073/pnas.1710519114.
5. Eaton-Fitch N, du Preez S, Cabanas H, Staines D, Marshall-Gradisnik S. A systematic review of natural killer cell profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome. Syst Rev. 2019;8:279. doi:10.1186/s13643-019-1202-6.
6. Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10(6):763. doi:10.3390/pathogens10060763.
7. Fallon BA, Levin ES, Schweitzer PJ, Hardesty D. Inflammation and central nervous system Lyme disease. Neurobiol Dis. 2010;37(3):534-541. doi:10.1016/j.nbd.2009.10.016.
8. Mozhgani SH, Rajabi F, Qurbani M, et al. Human herpesvirus 6 infection and risk of chronic fatigue syndrome: a systematic review and meta-analysis. Intervirology. 2022;65(1):49-57. doi:10.1159/000517930.
9. Brewer JH, Thrasher JD, Straus DC, Madison RA, Hooper D. Detection of mycotoxins in patients with chronic fatigue syndrome. Toxins (Basel). 2013;5(4):605-617. doi:10.3390/toxins5040605.
10. Bjørklund G, Dadar M, Mutter J, Aaseth J. The toxicology of mercury: current research and emerging trends. Environ Res. 2017;159:545-554. doi:10.1016/j.envres.2017.08.051.
11. Tomas C, Brown A, Strassheim V, et al. Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. PLoS One. 2017;12(10):e0186802. doi:10.1371/journal.pone.0186802.
12. Zhang S, Feng H, et al. Epstein-Barr virus regulates autophagy and mitochondrial metabolism during infection. Cell Mol Life Sci. 2018;75(21):4063-4077. doi:10.1007/s00018-018-2891-6.
13. Montoya JG, Kogelnik AM, Bhangoo M, et al. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. J Med Virol. 2013;85(12):2101-2109. doi:10.1002/jmv.23713.
14. Klimas NG, Broderick G, Fletcher MA. Biomarkers for chronic fatigue. Brain Behav Immun. 2012;26(8):1202-1210. doi:10.1016/j.bbi.2012.06.006.